BioArctic’s Lecanemab Data to be Unveiled at CTAD Conference

BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement.

BioArctic AB announced that its partner Eisai will present new data on their Alzheimer’s treatment, lecanemab, at the CTAD conference. The presentations will cover long-term treatment benefits, safety, and real-world clinical practice insights, potentially impacting the company’s market positioning and offering new options for Alzheimer’s treatment.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

More about BioArctic AB Class B

BioArctic AB is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s disease. Their primary product, Leqembi, is an antibody developed in collaboration with Eisai, targeting amyloid-beta protofibrils, which are believed to contribute to Alzheimer’s progression.

Average Trading Volume: 308,954

Technical Sentiment Signal: Buy

Current Market Cap: SEK26.13B

See more data about BIOA.B stock on TipRanks’ Stock Analysis page.